ReviewExpert opinion on drug discovery2026
The latest
Review in Expert opinion on drug discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionUveal melanoma (UM) is the most common primary intraocular malignancy in adults, but primary tumor treatment carries a high risk of permanent vision loss and does not adequately prevent metastatic progression. AREAS COVERED: This review covers current and emerging EXPERT OPINION: While traditional cell lines have provided an important foundation for UM research, emerging spheroid and patient-derived organoid models may more accurately represent in vivo tumor behavior and the tumor microenvironment. Pairing these 3D models with co-culture techniques could dramatically improve the representativeness of UM models. Researchers should consider testing promising therapeutics on a panel of models representing different UM subtypes, with particular attention to high-risk UM, such as those with BAP1 loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.